检索结果-南通市图书馆

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

老年肝癌患者系统治疗策略

医药导报 2024年第3期43卷 374-379页

作者：孙伊婷滕赞刘云鹏曲秀娟中国医科大学附属第一医院肿瘤内科沈阳110000 辽宁省肿瘤药物与生物治疗重点实验室沈阳110000 辽宁省恶性肿瘤临床医学研究中心沈阳110000

衰老是促进慢性肝病不同阶段发展的主要风险因素,与肝细胞癌的发生密切相关,老年和年轻肝癌患者的临床病理学特征及肿瘤微环境有显著区别。肝癌系统治疗领域发展日新月异,免疫检查点抑制剂联合靶向治疗极大改善了晚期肝癌患者的预后。... 详细信息

衰老是促进慢性肝病不同阶段发展的主要风险因素,与肝细胞癌的发生密切相关,老年和年轻肝癌患者的临床病理学特征及肿瘤微环境有显著区别。肝癌系统治疗领域发展日新月异,免疫检查点抑制剂联合靶向治疗极大改善了晚期肝癌患者的预后。老年肝癌患者治疗决策的选择需要考虑年龄相关的独特问题,在决策前需进行充分沟通和必要评估。通过大型临床研究的年龄亚组分析,可以推测老年肝癌患者能够从免疫联合治疗中获益,不应将高龄作为治疗策略选择的限制因素。然而,将临床试验中获得的疗效和安全性数据外推到真实世界中的老年人群具有一定局限性,针对老年肝癌患者的最佳诊疗方案仍有待大规模前瞻性临床研究进一步探索。

关键词：肝癌患者/老年系统治疗策略免疫检查点抑制剂

The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

在线全文

学校读者我要写书评

暂无评论

胰腺病学杂志(英文) 2024年第1期7卷 1-9页

作者： Cui Jiujie Fu Qihan Chen Xiaobing Wang Yanling Li Qi Wang Feng Li Zhihua Dai Guanghai Wang Yusheng Zhang Hongmei Liang Houjie Zhou Jun Yang Liu Wang Fenghua Zheng Leizhen Chen Xiaofeng Gong Ping Liu Jiang Yuan Ying Wang Lin Cheng Yuejuan Zhang Jun Zhou Yuhong Guo Weijian Zhan Xianbao Zou Zhengyun Li Da Zeng Shan Li Enxiao Li Zhiwei teng zan Cao Dan Kan Jie Xiong Jianping Quan Ming Yao Jiayu Yang Haiyan Wang Liwei Department of Medical Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou China Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China Department of Medical Oncology Shanghai General Hospital Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen University Guangzhou China Medical Oncology Chinese PLA General Hospital Beijing China Department of Gastrointestinal Oncology Shanxi Provincial Cancer Hospital Affiliated to Shanxi Medical University Taiyuan China Department of Clinical Oncology Xijing Hospital Air Force Medical University Xi’an China Department of Oncology and Southwest Cancer Center Southwest Hospital Third Military Medical University (Army Military Medical University) Chongqing China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing) Peking University Cancer Hospital &amp Institute Beijing China Cancer Center Department of Medical Oncology Zhejiang Provincial People’s Hospital People’s Hospital of Hangzhou Medical College Hangzhou China Department of Medical Oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China Department of Oncology the First Affiliated Hospital with Nanjing Medical University Nanjing China Department of Oncology The First Affiliated Hospital School of Medicine Shihezi University Shihezi China Department of Oncology People’s Hospital of Xinjia

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was ***: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS ***: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recomm

关键词： Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study

Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第20期136卷 2397-2411页

作者： Feng Jiao Jiujie Cui Deliang Fu Qi Li Zheng Wu zan teng Hongmei Zhang Jun Zhou Zhihong Zhang Xiaobing Chen Yuhong Zhou Yixiong Li Yiping Mou Renyi Qin Yongwei Sun Gang Jin Yuejuan Cheng Jian Wang Gang Ren Jiang Yue Guangxin Jin Xiuying Xiao Liwei Wang on behalf of Pancreatic Tumor Group,Society of Oncology,Chinese Medical Association Department of Oncology State Key Laboratory of Systems Medicine for CancerShanghai Cancer InstituteRenji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China Department of Pancreatic Surgery Huashan HospitalFudan UniversityShanghai 200040China Department of Oncology Shanghai General HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200080China Department of Hepatobiliary Surgery The First Affiliated Hospital of Xi’an Jiao Tong UniversityXi’anShaanxi 710061China Department of Oncology The First Hospital of China Medical UniversityShenyangLiaoning 110801China Department of Medical Oncology The First Affiliated Hospital of Air Force Medical UniversityXi’anShaanxi 710032China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Pathology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China Department of Oncology The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenan 450003China Department of Medical Oncology Zhongshan HospitalFudan UniversityShanghai 200032China Department of General Surgery Xiangya HospitalCentral South UniversityChangshaHunan 410008China Department of Gastrointestinal and Pancreatic Surgery Zhejiang Provincial People’s HospitalAffiliated People’s HospitalHangzhou Medical CollegeHangzhouZhejiang 310014China Department of Biliary-Pancreatic Surgery Affiliated Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Department of Biliary-Pancreatic Surgery Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China Department of Hepatobiliary Pancreatic Surgery Changhai HospitalNaval Medical UniversityShanghai 200433China Department of Medical Oncology Peking Union Medical College HospitalChinese Academy of Medical Sci

Pancreatic neuroendocrine neoplasms(pNENs)are rare and highly heterogeneous tumors originating from pluripotent stem cells with neuroendocrine differentiation in the pancreas,constituting approximately 3%of all pancreatic tumors.^([1])The global incidence of pNENs has been increasing recently,and most cases are sporadic and more common in women.^([1,2])pNENs are clinically divided into functioning and nonfunctioning tumors depending on whether the tumors are accompanied by a clinical syndrome related to specific hormone overproduction.

关键词： neoplasms neuroendocrine diagnosis

在线全文

学校读者我要写书评

暂无评论

哮喘豚鼠气道平滑肌细胞内钙释放通道的变化

中国药理学通报 2007年第1期23卷 47-51页

作者：封瑞李智滕赞曹禹中国医科大学药学院天然药物研究室辽宁沈阳110001

目的检测哮喘豚鼠气道平滑肌细胞(ASMCs)内钙释放通道功能的改变,探讨与支气管哮喘的关系,同时,寻找传代培养ASMCs的方法。方法以Flou-3/AM为细胞内钙离子示踪剂,观察ASMCs在工具药作用下细胞内钙离子浓度([Ca2+]i)的改变。结果①在ASMC... 详细信息

目的检测哮喘豚鼠气道平滑肌细胞(ASMCs)内钙释放通道功能的改变,探讨与支气管哮喘的关系,同时,寻找传代培养ASMCs的方法。方法以Flou-3/AM为细胞内钙离子示踪剂,观察ASMCs在工具药作用下细胞内钙离子浓度([Ca2+]i)的改变。结果①在ASMCs外无钙情况下,不同浓度ryanodine(5×10-5,10-4,2×10-4mol·L-1)作用于原代培养正常与哮喘ASMCs,[Ca2+]i迅速升高,哮喘组明显高于正常组(P0·05)。②传代培养哮喘ASMCs在10-4、2×10-4mol·L-1ryanodine作用下,[Ca2+]i迅速升高,与原代细胞比较无差异(P>0·05)。在浓度为5×10-5mol·L-1时,原代明显高于传代(P<0.01)。哮喘组传代ASMCs对10-4mol·L-1的histamine反应不明显。结论哮喘豚鼠ASMCs内钙释放通道(RyRs)功能升高,特定条件下,哮喘传代细胞仍然保持原代细胞内钙释放通道的特性。

关键词：哮喘气道平滑肌细胞(ASMCs) 钙离子

在线全文

学校读者我要写书评

暂无评论

数字普惠金融对农业全要素生产率的影响研究

金融理论探索 2024年第3期 40-51页

作者：昝金莉滕磊成都信息工程大学统计学院四川成都610100

“十四五”新时期,数字普惠金融对农业生产的服务支持作用越发显著。在探讨数字普惠金融如何影响农业全要素生产率的研究中,选择我国除港澳台地区外的31个省级行政区2011—2021年的面板数据,运用DEA-Malmquist指数模型,从产出、投入两... 详细信息

“十四五”新时期,数字普惠金融对农业生产的服务支持作用越发显著。在探讨数字普惠金融如何影响农业全要素生产率的研究中,选择我国除港澳台地区外的31个省级行政区2011—2021年的面板数据,运用DEA-Malmquist指数模型,从产出、投入两方面对农业全要素生产率进行了量化评估;构建固定效应检验模型,实证探究数字普惠金融在提升我国农业全要素生产率方面的作用;构建门槛效应回归模型,探讨二者之间是否存在非线性影响。研究结论为:第一,数字普惠金融的蓬勃发展显著推动了农业全要素生产率的提高,特别是在促进农业技术进步方面表现尤为突出,但其数字化程度的影响效应并不明显。第二,数字普惠金融在不同地域背景下所产生的影响会因地区发展水平的不同而存在差异。第三,数字普惠金融对农业全要素生产率的作用不仅与其自身的发展程度有关系,还与农村居民的收入水平高低有关。

关键词：数字普惠金融农业全要素生产率 DEA-Malmquist指数模型门槛机制

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

不可切除胰腺癌治疗策略的更新与意义

中国实用外科杂志 2018年第7期38卷 730-734页

作者：滕赞刘云鹏中国医科大学附属第一医院肿瘤内科辽宁沈阳110001

目前,不可切除胰腺癌治疗策略是以全身系统化疗为主,放疗、介入、姑息性手术等局部治疗为辅,达到减轻病人局部症状,提高生活质量,延长生存期的目的。体能较好病人推荐FOLFIRINOX或吉西他滨(GEM)联合白蛋白结合型紫杉醇方案化疗,中位生... 详细信息

目前,不可切除胰腺癌治疗策略是以全身系统化疗为主,放疗、介入、姑息性手术等局部治疗为辅,达到减轻病人局部症状,提高生活质量,延长生存期的目的。体能较好病人推荐FOLFIRINOX或吉西他滨(GEM)联合白蛋白结合型紫杉醇方案化疗,中位生存期可延长至接近1年,约15%局部晚期初始不可切除病人有可能转化为可切除。GEM联合厄洛替尼依然是各指南靶向药物的惟一一线推荐,抗肿瘤基质药物人重组透明质酸酶α(PEGPH20)有望取得突破性进展。美国国家综合癌症网络(NCCN)指南推荐程序性细胞死亡蛋白-1(PD-1)及其配体(PD-L1)抑制剂用于高度微卫星不稳定(MSI-H)或错配修复缺陷(dMMR)不可切除胰腺癌病人,免疫治疗进入二线标准推荐。强调多学科综合治疗协作组(MDT)模式及个体化精准治疗理念。

关键词：胰腺癌化疗免疫治疗靶向治疗治疗策略

滨蒿内酯对ryanodine介导哮喘豚鼠气道平滑肌细胞内钙释放的抑制作用

在线全文

学校读者我要写书评

暂无评论

中国现代医学杂志 2012年第4期22卷 24-28页

作者：滕赞王嫘李智中国医科大学附属第一医院肿瘤内科辽宁沈阳110001 中国医科大学附属第一医院老年病科辽宁沈阳110001 中国医科大学药学院药物毒理学教研室辽宁沈阳110001

目的该实验就滨蒿内酯(Scoparone,Sco)降低气道平滑肌细胞(airway smooth muscle Cells,ASMC)细胞内钙浓度(cytoplasmic Ca2+concentration,[Ca2+]i)的途径及平喘作用的机理进行初步的探讨。方法建立卵蛋白诱导的哮喘豚鼠模型,通过离体... 详细信息

目的该实验就滨蒿内酯(Scoparone,Sco)降低气道平滑肌细胞(airway smooth muscle Cells,ASMC)细胞内钙浓度(cytoplasmic Ca2+concentration,[Ca2+]i)的途径及平喘作用的机理进行初步的探讨。方法建立卵蛋白诱导的哮喘豚鼠模型,通过离体豚鼠气管环的舒缩实验和测定培养的ASMCs[Ca2+]i浓度的方法,分析Sco对哮喘豚鼠ryanodine受体介导的内钙释放的影响。结果显示在细胞外含钙或无钙时,预先给予Scoparone可抑制5μmol/L ryanodine引起的正常、哮喘组豚鼠离体气管环收缩反应;Scoparone可明显降低对照组及哮喘组豚鼠原代培养ASMCs[Ca2+]i水平且哮喘组更为明显(P<0.01);Scoparone明显降低原代培养的ASMCs[Ca2+]i对5μmol/L ryanodine的反应性(P<0.01)。结论 Sco明显降低正常和哮喘豚鼠原代培养的ASMCs[Ca2+]i,对后者的作用明显大于前者;Sco对ASMCs的[Ca2+]i降低作用主要是通过抑制细胞内钙释放途径实现的,明显抑制哮喘豚鼠ASMCs ryanodine受体介导的内钙释放。

关键词：滨蒿内酯气道高反应性 ryanodine 内钙释放

Altered ryanodine receptor functions of cultured airway smooth muscle cells in asthmatic guinea pig

在线全文

学校读者我要写书评

暂无评论

Altered ryanodine receptor functions of cultured airway smoo...

滨蒿内酯对豚鼠肥大细胞释放组胺、类胰蛋白酶及细胞内钙的影响

第十五届国际药理学大会

作者： Rui Feng Zhi Li zan teng Yu Cao Department of natural pharmacy School of Pharmaceutical Science China Medical University Shenyang 110001 China

＜正＞ The functional changes of Ca2+- induced Ca2+ release channels of airway smooth muscle cells （ ASMCs） were investigated in asthmatic guinea pig. [ Ca2+]i was measured with a fluorescent Ca2 + indicator （Hou - 3/AM）. In extracellular Ca2+ - free condition, Ryanodine, 50μ M to 200μ M, induced [Ca2+ ]i increase in primary cultured ASMCs in control and asthmatic groups, with the more significant increase of [ Ca2 + ] i in asthmatic group （ P ＜ 0. 01）. Ryanodine （50 μM） induced [ Ca2 + ] i increase in primary cultured ASMCs of asthmatic group was higher than subcultured cells （P ＜ 0.01）, while in 100 μ and 200 μ ryanodine, the [Ca2+ ]i increase in primary cultured ASMCs of asthmatic group and subcultured was not significant different （P ＞ 0.05）. In extracellular Ca2 + - free condition, although histamine （100 μ） increased [ Ca2 + ] i in primary cultured ASMCs in control and asthmatic groups, the increase was not significant different between the two groups （P ＞ 0.05）. Conclusion Ryanodine receptor, but not IP3 receptor of ASMCs of asthmatic guinea pig showed *** specified condition, the characteristics of ryanodine receptor still retain in subcultured ASMCs of asthmatic guinea pig.

关键词： [Ca2+]i ry anodine receptor. asthma airway smooth muscle cell

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

中国现代医学杂志 2012年第13期22卷 1-5页

作者：滕赞姜晖王嫘李智中国医科大学附属第一医院肿瘤内科辽宁沈阳110001 中国医科大学药学院药物毒理学教研室辽宁沈阳110001 中国医科大学附属第一医院老年病科辽宁沈阳110001

目的滨蒿内酯(Soparone,Sco.)通过松弛气道平滑肌、清除气道氧自由基、抑制气道炎症等多种途径起到抗炎平喘作用,该实验基于前期所做的研究工作,进一步探讨了Sco对肥大细胞(mast cells,MCs)脱颗粒及其炎症介质的释放作用的影响及可能的... 详细信息

目的滨蒿内酯(Soparone,Sco.)通过松弛气道平滑肌、清除气道氧自由基、抑制气道炎症等多种途径起到抗炎平喘作用,该实验基于前期所做的研究工作,进一步探讨了Sco对肥大细胞(mast cells,MCs)脱颗粒及其炎症介质的释放作用的影响及可能的调控途径。方法不同浓度的Sco(10-5、10-6和10-7mol/L)分别作用于正常及致敏MCs,并设立正常及致敏MCs的溶剂对照组(control,asthma),比较各组MCs脱颗粒百分数、类胰蛋白酶活力、组胺释放率及MCs细胞内钙([Ca2+])i的变化。结果 1×10-5和1×10-6mol/L Sco.组MCs脱颗粒百分数分别为(39.10±2.81)%和(11.40±2.37)%,明显低于asthma组的(78.90±4.12)%(P<0.05),且以上Sco.组MCs的组胺和类胰蛋白酶释放亦较asthma组显著减少(P<0.05);在无细胞外钙条件下,不同浓度的Sco(10-5、10-6和10-7mol/L)对正常MCs[Ca2+]i的影响分别为(-12.1±2.2)%、(-6.1±2.4)%和(-2.1±0.7)%,对致敏MCs[Ca2+]i的影响分别为(-75.6±2.2)%、(-33.9±2.5)%和(-4.0±0.02)%,相同浓度Sco.对正常组和致敏组MCs[Ca2+]i的降低作用的组间差异有显著性(P<0.05)。结论 Sco.可剂量依赖性抑制豚鼠MCs脱颗粒从而抑制MCs组胺及类胰蛋白酶的释放;Sco.能够抑制豚鼠正常MCs以及致敏MCs[Ca2+]i水平。

关键词：哮喘肥大细胞脱颗粒组胺类胰蛋白酶细胞内钙